$CATX
Perspective Therapeutics Inc Stock $catx

$catx Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000114420416100413 Filed on May 10, 2016

Income Statement

Concept	2016 Q2	2016 Q1	2015 Q2
Revenue	$1.120M	$1.198M	$1.341M
YoY Change	-16.46%	3.44%	41.2%
Cost Of Revenue	$1.170M	$1.132M	$1.140M
YoY Change	2.63%	2.64%	4.59%
Gross Profit	-$48.00K	$66.00K	$205.0K
YoY Change	-123.42%	19.57%	-250.53%
Gross Profit Margin	-4.29%	5.51%	15.29%
Selling, General & Admin	$1.520M	$1.211M	$1.150M
YoY Change	32.17%	25.52%	16.16%
% of Gross Profit		1834.85%	561.08%
Research & Development	$140.0K	$183.0K	$160.0K
YoY Change	-12.5%	29.42%	-20.0%
% of Gross Profit		277.27%	78.06%
Depreciation & Amortization	$140.0K	$140.0K	$150.0K
YoY Change	-6.67%	0.0%	-16.67%
% of Gross Profit		212.12%	73.18%
Operating Expenses	$1.200M	$1.394M	$1.300M
YoY Change	-7.69%	26.02%	10.17%
Operating Profit	-$1.248M	-$1.327M	-$1.095M
YoY Change	13.97%	26.26%	-16.8%
Interest Expense	$70.00K	$0.00	$70.00K
YoY Change	0.0%	-100.0%	-119.44%
% of Operating Profit
Other Income/Expense, Net	-$460.0K	$132.0K	$0.00
YoY Change		35.44%
Pretax Income	-$1.180M	-$1.200M	-$1.030M
YoY Change	14.56%	26.32%	-38.69%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$1.185M	-$1.195M	-$1.035M
YoY Change	14.53%	25.32%	-38.33%
Net Earnings / Revenue	-105.8%	-99.75%	-77.17%
Basic Earnings Per Share
Diluted Earnings Per Share	-$21.44K	-$21.81K	-$18.76K
COMMON SHARES
Basic Shares Outstanding	55.01M shares	55.01M shares	54.91M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q2	2016 Q1	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.39M	$11.61M	$14.59M
YoY Change	-15.08%	14.27%	-17.48%
Cash & Equivalents	$10.14M	$5.694M	$5.227M
Short-Term Investments	$2.250M	$5.910M	$9.360M
Other Short-Term Assets	$27.00K	$290.0K	$26.69K
YoY Change	1.15%	31.82%	0.0%
Inventory	$334.0K	$457.3K	$404.0K
Prepaid Expenses
Receivables	$600.0K	$880.0K	$1.049M
Other Receivables	$108.00	$5.098K	$19.62K
Total Short-Term Assets	$13.63M	$13.24M	$16.33M
YoY Change	-16.52%	11.36%	-15.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$577.0K	$415.7K	$574.8K
YoY Change	0.38%	-37.02%	-43.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$2.970M	$5.190M	$5.110M
YoY Change	-41.88%	-48.87%	-5.37%
Other Assets	$151.0K	$222.5K	$245.0K
YoY Change	-38.38%	-65.76%	-7.21%
Total Long-Term Assets	$4.473M	$6.556M	$6.678M
YoY Change	-33.02%	-43.92%	-8.95%
TOTAL ASSETS
Total Short-Term Assets	$13.63M	$13.24M	$16.33M
Total Long-Term Assets	$4.473M	$6.556M	$6.678M
Total Assets	$18.10M	$19.80M	$23.00M
YoY Change	-21.31%	-16.05%	-13.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$610.0K	$730.0K	$500.0K
YoY Change	22.0%	65.91%	-12.28%
Accrued Expenses	$480.0K	$480.0K	$590.0K
YoY Change	-18.64%	9.09%	1.72%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.094M	$1.212M	$1.092M
YoY Change	0.17%	37.76%	-5.35%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$610.0K	$1.060M	$1.130M
YoY Change	-46.02%	-4.5%	-21.53%
Total Long-Term Liabilities	$610.0K	$1.060M	$1.130M
YoY Change	-46.02%	-4.5%	-21.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.094M	$1.212M	$1.092M
Total Long-Term Liabilities	$610.0K	$1.060M	$1.130M
Total Liabilities	$1.701M	$2.271M	$2.221M
YoY Change	-23.41%	14.25%	-14.36%
SHAREHOLDERS EQUITY
Retained Earnings	-$66.44M	-$65.26M	-$61.73M
YoY Change	7.63%	7.51%	6.34%
Common Stock	$82.84M	$82.78M	$82.52M
YoY Change	0.39%	150731.64%	150757.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00	$0.00	$8.390K
YoY Change	-100.0%	-100.0%	0.0%
Treasury Stock Shares	0.000 shares	0.000 shares	13.20K shares
Shareholders Equity	$16.40M	$17.52M	$20.78M
YoY Change
Total Liabilities & Shareholders Equity	$18.10M	$19.80M	$23.00M
YoY Change	-21.31%	-16.06%	-13.36%

Cashflow Statement

Concept	2016 Q2	2016 Q1	2015 Q2
OPERATING ACTIVITIES
Net Income	-$1.185M	-$1.195M	-$1.035M
YoY Change	14.53%	25.32%	-38.33%
Depreciation, Depletion And Amortization	$140.0K	$140.0K	$150.0K
YoY Change	-6.67%	0.0%	-16.67%
Cash From Operating Activities	-$1.200M	-$760.0K	-$630.0K
YoY Change	90.48%	-32.74%	-36.36%
INVESTING ACTIVITIES
Capital Expenditures	-$230.0K	-$210.0K	-$60.00K
YoY Change	283.33%	425.0%	200.0%
Acquisitions
YoY Change
Other Investing Activities	$5.880M	$5.980M	$4.750M
YoY Change	23.79%	550.0%	-130.84%
Cash From Investing Activities	$5.660M	$5.760M	$4.700M
YoY Change	20.43%	562.07%	-130.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	70.00K
YoY Change	-100.0%		-82.05%
NET CHANGE
Cash From Operating Activities	-1.200M	-760.0K	-630.0K
Cash From Investing Activities	5.660M	5.760M	4.700M
Cash From Financing Activities	0.000	0.000	70.00K
Net Change In Cash	4.460M	5.000M	4.140M
YoY Change	7.73%	-2023.08%	-125.84%
FREE CASH FLOW
Cash From Operating Activities	-$1.200M	-$760.0K	-$630.0K
Capital Expenditures	-$230.0K	-$210.0K	-$60.00K
Free Cash Flow	-$970.0K	-$550.0K	-$570.0K
YoY Change	70.18%	-49.54%	-41.24%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2016Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	5098	USD
CY2015Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	19615	USD
CY2016Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	288977	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	263597	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	13240163	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	16325522	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	415675	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	574840	USD
CY2016Q1	us-gaap	Long Term Investments LongTermInvestments	5191960	USD
CY2015Q2	us-gaap	Long Term Investments LongTermInvestments	5106775	USD
CY2016Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181368	USD
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181262	USD
CY2016Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	544363	USD
CY2015Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	569854	USD
CY2016Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	222529	USD
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	245031	USD
	dei	Trading Symbol TradingSymbol	ISR
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55010619	shares
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5694339	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5226740	USD
CY2016Q1	us-gaap	Short Term Investments ShortTermInvestments	5910756	USD
CY2015Q2	us-gaap	Short Term Investments ShortTermInvestments	9362574	USD
CY2016Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	883702	USD
CY2015Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	1049041	USD
CY2016Q1	us-gaap	Inventory Net InventoryNet	457291	USD
CY2015Q2	us-gaap	Inventory Net InventoryNet	403955	USD
	dei	Document Period End Date DocumentPeriodEndDate	2016-03-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	IsoRay, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0000728387
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
CY2016Q1	us-gaap	Assets Assets	19796058	USD
CY2015Q2	us-gaap	Assets Assets	23003284	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	458636	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	833887	USD
CY2015Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	204760	USD
CY2015Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	55526	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-953553	USD
CY2016Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	732018	USD
CY2015Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	498253	USD
CY2016Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	97679	USD
CY2015Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	124131	USD
CY2016Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	164544	USD
CY2015Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	129500	USD
CY2016Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	119165	USD
CY2015Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	212795	USD
CY2016Q1	us-gaap	Accrued Vacation Current AccruedVacationCurrent	98874	USD
CY2015Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	127515	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1212280	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1092194	USD
CY2016Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	45000	USD
CY2015Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	181000	USD
CY2016Q1	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	1013782	USD
CY2015Q2	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	947849	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	55010	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	54968	USD
CY2016Q1	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2015Q2	us-gaap	Treasury Stock Value TreasuryStockValue	8390	USD
CY2016Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	82727429	USD
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	82467111	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-65257502	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61731507	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	17524996	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	20782241	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19796058	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23003284	USD
CY2016Q1	us-gaap	Liabilities Liabilities	2271062	USD
CY2015Q2	us-gaap	Liabilities Liabilities	2221043	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1198701	USD
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1158109	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1132397	USD
CY2015Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1102912	USD
CY2016Q1	us-gaap	Gross Profit GrossProfit	66304	USD
CY2015Q1	us-gaap	Gross Profit GrossProfit	55197	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	183187	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	141399	USD
CY2016Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	300995	USD
CY2015Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	374876	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	909144	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	589934	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	1393326	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	1106209	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1327022	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1051012	USD
CY2016Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	53725	USD
CY2015Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	68954	USD
CY2016Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	78000	USD
CY2015Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	28605	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	0	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	100	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	131725	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	97459	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-1195297	USD
CY2016Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2658	USD
CY2015Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2658	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1197955	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-956211	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	10031758	USD
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	85185	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.48
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.46
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55022668	shares
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54883551	shares
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	3649031	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	3265795	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3472357	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3303364	USD
	us-gaap	Gross Profit GrossProfit	176674	USD
	us-gaap	Gross Profit GrossProfit	-37569	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	385325	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1032402	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2785539	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1703825	USD
	us-gaap	Operating Expenses OperatingExpenses	4004751	USD
	us-gaap	Operating Expenses OperatingExpenses	3194863	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3828077	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3232432	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	167032	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	214009	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	136000	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	375605	USD
	us-gaap	Interest Expense InterestExpense	950	USD
	us-gaap	Interest Expense InterestExpense	3551	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	302082	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	586063	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3525995	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2646369	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	7974	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	7974	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3533969	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2654343	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55010619	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54878297	shares
	isr	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	0	USD
	isr	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	8607	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	412170	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	439223	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	25494	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	34923	USD
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	65933	USD
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	60278	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	229442	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	64360	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-165339	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	116817	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	125536	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	104818	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-14517	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-43154	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-111	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9171	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	233765	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-135198	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-26452	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y4D
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	38031	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	35044	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-23469	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-93630	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-146746	USD
	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	-28641	USD
	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	-5633	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2675727	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2892464	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	259517	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	77963	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2992	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	14016	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	9558812	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	6106994	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	9110673	USD
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	4744580	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	106	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	40	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	3104018	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-3915514	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	70789	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	49940	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	145274	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	39308	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	205431	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	467599	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-6602547	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7680073	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1077526	USD
	isr	Supplemental Common Stock Warrant Liability Reclassification SupplementalCommonStockWarrantLiabilityReclassification	0	USD
	isr	Supplemental Common Stock Warrant Liability Reclassification SupplementalCommonStockWarrantLiabilityReclassification	17395	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	10632	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	10632	USD
	isr	Federal Deposit Insurance Corporation Limits On Deposits In Financial Institutions FederalDepositInsuranceCorporationLimitsOnDepositsInFinancialInstitutions	250000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2774925	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2512859	shares
CY2016Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	223588	USD
CY2015Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	143669	USD
CY2016Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	225978	USD
CY2016Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7725	USD
CY2016Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7482445	USD
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7114836	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	166066	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21452	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	229442	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	64360	USD
CY2016Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	337350	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y4M2D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	56260	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	133564	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2380060	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2294065	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1966762	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y8M16D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y7M28D
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	289393	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	27469	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	145275	USD
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7001671	shares
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7001671	shares
CY2015Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	13200	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	282800	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	274200	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.48
CY2016Q1	isr	Percentage Of Royalty Rate Payable PercentageOfRoyaltyRatePayable	0.01	pure
CY2016Q1	us-gaap	Area Of Land AreaOfLand	4.2	acre
CY2016Q1	isr	Number Of Employees Commitment NumberOfEmployeesCommitment	25	pure
CY2015Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	385800	shares
CY2016Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	360800	shares
	isr	Class Of Warrant Or Right Expired In Period ClassOfWarrantOrRightExpiredInPeriod	25000	shares
CY2015Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.22
CY2016Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.17
	isr	Classofwarrantorrightexpiredinperiodweightedaverageexercisepriceofwarrantsorrights Classofwarrantorrightexpiredinperiodweightedaverageexercisepriceofwarrantsorrights	2.00
	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	6000	USD
	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	6000	USD
	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	6000	USD
CY2016Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	2000	USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-6512	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Inventory Write Down InventoryWriteDown	72200	USD
	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	8390	USD
	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	0	USD
CY2016Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	30000	USD
CY2015Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	30000	USD
CY2016Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	192998329	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	192998329	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55010619	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55010619	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54967559	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54967559	shares
CY2016Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0px"> <div> </div> </td> <td style="TEXT-ALIGN: left; WIDTH: 0.5in"> <div><b><font style="BACKGROUND-COLOR: transparent"> 2.</font></b></div> </td> <td style="TEXT-ALIGN: justify"> <div><b><font style="BACKGROUND-COLOR: transparent">New Accounting Pronouncements</font></b></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b><font style="BACKGROUND-COLOR: transparent">  </font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="BACKGROUND-COLOR: transparent">In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes the revenue recognition requirements in FASB Accounting Standards Codification (ASC) Topic 605, Revenue Recognition. The guidance requires that an entity recognize revenue in a way that depicts the transfer of promised goods or services to customers in the amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods and services. The guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, and is to be applied retrospectively, with early application not permitted. The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="BACKGROUND-COLOR: transparent">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="BACKGROUND-COLOR: transparent">In July 2015, the FASB issued ASU No. 2015-11 Inventory. The guidance requires an entity’s management to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early application is permitted.  The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="BACKGROUND-COLOR: transparent">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="BACKGROUND-COLOR: transparent">In January 2016, the FASB issued ASU No. 2016-01 Financial Instruments Overall. The guidance requires an entity’s management to measure equity investments except those accounted for under the equity method of accounting or those that result in consolidation of the investee to be measured at fair value; simplifies the impairment assessment of equity investments; eliminates the requirement to disclose the fair value of financial instruments measured at amortized cost for non-public entities: eliminates the requirement for a public entity to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet; requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes; requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments; requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or the accompanying notes to the financial statements; and clarifies that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early application is not permitted except as contained in the early adoption guidance.  The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7898120	USD
CY2015Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7689676	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	482500	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	20000	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	462500	shares
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	10632	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	10632	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	6000	USD
CY2015Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	2000	USD
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0051	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0151	pure

Files In Submission

Name	View Source	Status
0001144204-16-100413-index-headers.html	Edgar Link	pending
0001144204-16-100413-index.html	Edgar Link	pending
0001144204-16-100413.txt	Edgar Link	pending
0001144204-16-100413-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
isr-20160331.xml	Edgar Link	completed
isr-20160331.xsd	Edgar Link	pending
isr-20160331_cal.xml	Edgar Link	unprocessable
isr-20160331_def.xml	Edgar Link	unprocessable
isr-20160331_lab.xml	Edgar Link	unprocessable
isr-20160331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v437864_10q.htm	Edgar Link	pending
v437864_ex31-1.htm	Edgar Link	pending
v437864_ex31-2.htm	Edgar Link	pending
v437864_ex32.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CATX
Perspective Therapeutics Inc Stock $catx

2016 Q2 Form 10-Q Financial Statement

#000114420416100413 Filed on May 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX Perspective Therapeutics Inc Stock $catx

2016 Q2 Form 10-Q Financial Statement

#000114420416100413 Filed on May 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX
Perspective Therapeutics Inc Stock $catx